ERBB2 and breast cancer: Taken together, the ORR of 44% reported by Li et al. in ERBB2-mutated NSCLC is consistent with the rates reported by studies on breast cancer; however, the median PFS of 5 months in ERBB2-mutated NSCLC is shorter than the 10-month PFS in breast cancer.